What insurance policy changes affect code C92.41?

There are 2 tracked policy changes affecting code C92.41, including updates from Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C92.41?

Payers that have issued tracked updates for code C92.41 include: Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C92.41 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C92.41. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C92.41?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

C92.41 Insurance Policy Changes

ICD-10 C92.41 is officially defined as "Acute promyelocytic leukemia, in remission." code C92.41 is referenced in 2 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C92.41 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid Leukemia
Genetic testing for FLT3 internal tandem duplication (FLT3-ITD), NPM1, CEBPA, IDH1 and IDH2 variants may be considered medically necessary in cytogenetically normal acute myeloid leukemia (AML). Genetic testing for these variants is considered investigational in all other situations, and testing for FLT3 tyrosine kinase domain (FLT3-TKD) variants is considered investigational. Testing for FLT3, NPM1 and CEBPA variants to detect minimal residual disease is also considered investigational, and the testing is intended to guide management decisions in individuals who would receive treatment other than low-dose chemotherapy or best supportive care.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
A 07/24/2026 review revised the policy statement on allogeneic HCT using a reduced-intensity conditioning regimen to remove the reference to Policy Guidelines, and the Code Reference section was updated to remove ICD-9 procedure and diagnosis codes. Allogeneic HCT with myeloablative conditioning may be considered medically necessary for poor- to intermediate-risk AML in first complete remission and for certain refractory or relapsed AML, while autologous HCT may be considered for AML in CR1 or beyond, or relapsed AML, in individuals who are not candidates for allogeneic HCT.

Watch C92.41

Get one email when a payer policy names C92.41, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Genetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid Leukemia

Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

What insurance policy changes affect code C92.41?

Which payers have updated policy for code C92.41?

How do I get notified when code C92.41 policy changes?

Why do payers change policies for code C92.41?